CD63 and chronic myelogenous leukemia, BCR-ABL1 positive: This study revealed deregulation of asymmetric stem cell division markers during chronic myeloid leukemia (CML) progression, with pronounced downregulation of five key genes—CD63, SELL, NUMB, HK2, and LAMP2—during blast crisis compared to the chronic phase.